Direct to consumer (DTC) genomic services facilitate the personalized and participatory aspects of “P4” medicine, but raise questions regarding use of genomic data in providing predictive and preventive healthcare. We illustrate the issues involved by describing a pregnancy management case in which a treatment plan was modified based on a DTC result. A woman whose personal and family history were otherwise unremarkable for thromboembolism learned through DTC testing about the presence of a prothrombin (factor 2) gene mutation (rs1799963). Twice daily injections of enoxaparin were recommended throughout pregnancy for this patient who, without prior knowledge of this mutation, would not have been offered such therapy. Moreover, genetically based medical guidelines are a moving target, and treatment of thrombophilic conditions in asymptomatic patients is controversial. We address the state of the art in actionable personalized medicine with respect to clotting disorders in pregnancy, as well as other factors at play— economics, patient preference, and clinical decision support. We also discuss what steps are needed to increase the utility of genomic data in personalized medicine by collecting information and converting it into actionable knowledge.
Hood, L.; Flores, M. A personal view on systems medicine and the emergence of proactive P4 medicine: Predictive, preventive, personalized and participatory. New Biotechnol. 2012, 29, 613–624.
[3]
Tian, Q.; Price, N.D.; Hood, L. Systems cancer medicine: Towards realization of predictive, preventive, personalized and participatory (P4) medicine. J. Intern. Med. 2012, 271, 111–121, doi:10.1111/j.1365-2796.2011.02498.x.
[4]
Auffray, C.; Charron, D.; Hood, L. Predictive, preventive, personalized and participatory medicine: Back to the future. Genome Med. 2010, 2, doi:10.1186/gm178.
[5]
Harmon, K. Genome Sequencing for the Rest of Us. Scientific American. 2010. Available online: http://www.scientificamerican.com/article.cfm?id=personal-genome-sequencing (accessed on 24 August 2012).
[6]
Guttmacher, A.E.; Collins, F.S. Genomic medicine-A primer. N. Engl. J. Med. 2002, 347, 1512–1520, doi:10.1056/NEJMra012240.
[7]
Trusheim, M.R.; Berndt, E.R.; Douglas, F.L. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 2007, 6, 287–293.
[8]
National Research Council. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Available online: http://www.ucsf.edu/sites/default/files/documents/new-taxonomy.pdf (accessed on 24 August 2012).
[9]
Evans, W.E.; Relling, M.V. Moving towards individualized medicine with pharmacogenomics. Nature 2004, 429, 464–468.
Burke, W.; Psaty, B.M. Personalized medicine in the era of genomics. JAMA 2007, 298, 1682–1684, doi:10.1001/jama.298.14.1682.
[12]
Wu, S. 23andMe Inc.: Mountain View, CA, USA, 2012.
[13]
Franco, R.F.; Santos, S.E.; Elion, J.; Tavella, M.H.; Zago, M.A. Prevalence of the G20210A polymorphism in the 3'-untranslated region of the prothrombin gene in different human populations. Acta Haematol. 1998, 100, 9–12, doi:10.1159/000040854.
[14]
Pihusch, R.; Buchholz, T.; Lohse, P.; Rubsamen, H.; Rogenhofer, N.; Hasbargen, U.; Hiller, E.; Thaler, C.J. Thrombophilic gene mutations and recurrent spontaneous abortion: Prothrombin mutation increases the risk in the first trimester. Am. J. Reprod. Immunol. 2001, 46, 124–131.
[15]
Alfirevic, Z.; Roberts, D.; Martlew, V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur. J. Obstet. Gynecol. Reprod. Biol. 2002, 101, 6–14, doi:10.1016/S0301-2115(01)00496-1.
[16]
Wu, O.; Robertson, L.; Twaddle, S.; Lowe, G.D.; Clark, P.; Greaves, M.; Walker, I.D.; Langhorne, P.; Brenkel, I.; Regan, L.; et al. Screening for thrombophilia in high-risk situations: Systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol. Assess. 2006, 10, 1–110.
Jacobsen, A.F.; Dahm, A.; Bergrem, A.; Jacobsen, E.M.; Sandset, P.M. Risk of venous thrombosis in pregnancy among carriers of the factor V Leiden and the prothrombin gene G20210A polymorphisms. J. Thromb Haemost. 2010, 8, 2443–2449, doi:10.1111/j.1538-7836.2010.04038.x.
[19]
Peters, E.; Hibbard, J.; Slovic, P.; Dieckmann, N. Numeracy skill and the communication, comprehension, and use of risk-benefit information. Health Aff. (Millwood) 2007, 26, 741–748.
[20]
James, A.H.; Jamison, M.G.; Brancazio, L.R.; Myers, E.R. Venous thromboembolism during pregnancy and the postpartum period: Incidence, risk factors, and mortality. Am. J. Obstet. Gynecol. 2006, 194, 1311–1315, doi:10.1016/j.ajog.2005.11.008.
[21]
EGAPP Working Group. Recommendations from the EGAPP Working Group: Routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. Genet. Med. 2011, 13, 67–76.
[22]
Spector, E.B.; Grody, W.W.; Matteson, C.J.; Palomaki, G.E.; Bellissimo, D.B.; Wolff, D.J.; Bradley, L.A.; Prior, T.W.; Feldman, G.; Popovich, B.W.; et al. Technical standards and guidelines: venous thromboembolism (Factor V Leiden and prothrombin 20210G>A testing): A disease-specific supplement to the standards and guidelines for clinical genetics laboratories. Genet. Med. 2005, 7, 444–453, doi:10.1097/01.GIM.0000172641.57755.3A.
[23]
Lockwood, C.; Wendel, G. Practice bulletin No. 124: Inherited thrombophilias in pregnancy. Obstet. Gynecol. 2011, 118, 730–770, doi:10.1097/AOG.0b013e3182310c6f.
[24]
Stead, W.W.; Searle, J.R.; Fessler, H.E.; Smith, J.W.; Shortliffe, E.H. Biomedical informatics: Changing what physicians need to know and how they learn. Acad. Med. 2011, 86, 429–434, doi:10.1097/ACM.0b013e3181f41e8c.
[25]
McGinnis, J.M. Evidence-based medicine-Engineering the Learning Healthcare System. Stud. Health Technol. Inform. 2010, 153, 145–157.
